Stockscreener 앱 받기
24.86
0.77%
0.19
시간 외 거래:
24.86
전일 마감가:
$24.67
열려 있는:
$24.6
하루 거래량:
331.15K
Relative Volume:
0.61
시가총액:
$990.97M
수익:
$734.86M
순이익/손실:
$5.14M
주가수익비율:
198.88
EPS:
0.125
순현금흐름:
$132.71M
1주 성능:
+6.97%
1개월 성능:
-3.94%
6개월 성능:
+6.19%
1년 성능:
-3.79%
1일 변동 폭
$24.49
$25.04
1주일 범위
$23.32
$25.04
52주 변동 폭
$18.80
$27.66
Pacira Biosciences Inc Stock (PCRX) Company Profile
명칭
Pacira Biosciences Inc
전화
650-242-8052
주소
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
24.86 | 949.91M | 734.86M | 5.14M | 132.71M | 0.125 |
TAK
Takeda Pharmaceutical Co Adr
|
18.24 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.16 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.93 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.17 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
512.88 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Equal Weight |
| 2025-11-17 | 개시 | H.C. Wainwright | Buy |
| 2025-07-25 | 업그레이드 | Truist | Hold → Buy |
| 2025-01-30 | 업그레이드 | Truist | Sell → Hold |
| 2024-08-13 | 다운그레이드 | Truist | Buy → Sell |
| 2024-08-12 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2024-08-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-03-07 | 재개 | JP Morgan | Overweight |
| 2023-12-20 | 개시 | Raymond James | Outperform |
| 2023-08-03 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | 재개 | Wedbush | Outperform |
| 2022-10-21 | 재개 | Jefferies | Buy |
| 2022-01-03 | 재개 | JP Morgan | Overweight |
| 2021-07-26 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-04-21 | 재개 | JP Morgan | Neutral |
| 2021-04-09 | 개시 | Berenberg | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-02-11 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | 재확인 | Needham | Buy |
| 2020-05-27 | 개시 | Guggenheim | Neutral |
| 2020-04-07 | 개시 | Northland Capital | Outperform |
| 2020-03-20 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-24 | 개시 | SunTrust | Buy |
| 2020-01-23 | 개시 | SunTrust | Buy |
| 2019-11-06 | 개시 | BTIG Research | Buy |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-05-06 | 업그레이드 | Mizuho | Underperform → Neutral |
| 2019-05-02 | 업그레이드 | Stifel | Sell → Hold |
| 2019-02-01 | 다운그레이드 | Mizuho | Neutral → Underperform |
| 2018-08-06 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | 재확인 | H.C. Wainwright | Buy |
| 2018-03-21 | 재확인 | Mizuho | Neutral |
| 2018-02-16 | 다운그레이드 | Needham | Buy → Hold |
| 2018-01-19 | 개시 | Seaport Global Securities | Buy |
| 2018-01-04 | 재확인 | Canaccord Genuity | Buy |
| 2018-01-03 | 개시 | Leerink Partners | Mkt Perform |
모두보기
Pacira Biosciences Inc 주식(PCRX)의 최신 뉴스
Pacira BioSciences Inc (PCRX) Stock Up 3.5% and Still Undervalued -- GF Score: 81/100 - GuruFocus
Foster & Motley Inc. Buys New Holdings in Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira (PCRX) Q2 2026 Results: Reported EPS Tops Expectations in Latest Trading; Post-Earnings: The Stock Gains 1.67% for the Current SessionBalance Sheet Strength - Vinanet
Rice Hall James & Associates LLC Purchases Shares of 93,396 Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences Inc (PCRX) Chief Medical Officer Jonathan Slo - GuruFocus
Pacira BioSciences (NASDAQ:PCRX) Insider Jonathan Slonin Sells 3,040 Shares of Stock - MarketBeat
Pacira BioSciences (PCRX) CMO sells 3,040 shares in 10b5-1 plan - Stock Titan
Pacira (PCRX) Daily Price Brief: Records a 2.17% Increase to $23.75 in Latest Trading; Technical Focus: $22.56 and $24.94 Define the Nearby Reference Levels on the DayBPI Bull Correction - vinanet.vn
Pacira BioSciences (NASDAQ: PCRX) faces $70.6K share sale in 2026 - Stock Titan
Pacira BioSciences (NASDAQ:PCRX) Coverage Initiated at Truist Financial - MarketBeat
Truist Financial Upgrades Pacira BioSciences(PCRX.US) to Buy Rating, Raises Target Price to $30 - Moomoo
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Pacira Biosciences (NASDAQ:PCRX): A Value Play with Fundamentals Intact - ChartMill
Barclays Maintains Pacira BioSciences(PCRX.US) With Hold Rating, Maintains Target Price $25 - Moomoo
Empowered Funds LLC Buys 49,171 Shares of Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences (NASDAQ:PCRX) Lowered to "Buy" Rating by Wall Street Zen - MarketBeat
Wedge Capital Management L L P NC Purchases New Stake in Pacira BioSciences, Inc. $PCRX - MarketBeat
Assenagon Asset Management S.A. Acquires Shares of 101,429 Pacira BioSciences, Inc. $PCRX - MarketBeat
(PCRX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Pacira BioSciences (PCRX) Is Down 7.1% After Advancing PCRX-201 Gene Therapy With Positive Phase 1 Data - Sahm
Pacira BioSciences, Inc. (PCRX) Investor Outlook: Navigating a 22.80% Potential Upside in Non-Opioid Solutions - DirectorsTalk Interviews
J.P. Morgan Maintains Pacira BioSciences(PCRX.US) With Sell Rating, Maintains Target Price $23 - Moomoo
Hennion & Walsh Asset Management Inc. Buys 48,124 Shares of Pacira BioSciences, Inc. $PCRX - MarketBeat
Is Pacira BioSciences (PCRX) Quietly Reframing Its Non‑Opioid Strategy Around PCRX‑201 Gene Therapy? - Yahoo Finance
Pacira BioSciences: Reimbursement Is Turning An Old Franchise Into A New Growth Platform - Seeking Alpha
Pacira BioSciences (NASDAQ:PCRX) Upgraded by Wall Street Zen to Strong-Buy Rating - MarketBeat
State Street Corporation (NYSE: STT) discloses 5.2% ownership in Pacira BioSciences - Stock Titan
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Pacira BioSciences, Inc. (PCRX) Stock forecasts - Yahoo Finance UK
Pacira BioSciences (PCRX) Could Be 35% Undervalued On Phase 1 Gene Therapy Progress - Yahoo Finance
Here's What Analysts Are Forecasting For Pacira BioSciences, Inc. (NASDAQ:PCRX) After Its Second-Quarter Results - Moomoo
Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases - The Manila Times
Pacira BioSciences, Inc. $PCRX Shares Purchased by Pacer Advisors Inc. - MarketBeat
Pacira BioSciences, Inc. (PCRX) Stock Forecasts - Yahoo! Finance Canada
One knee injection study followed pain and function for 2 years - Stock Titan
Pacira BioSciences, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:PCRX) 2026-08-05 - Seeking Alpha
Pacira BioSciences (NASDAQ:PCRX) Trading Down 7.9%Should You Sell? - MarketBeat
Royal Bank Of Canada Forecasts Strong Price Appreciation for Pacira BioSciences (NASDAQ:PCRX) Stock - marketbeat.com
H.C. Wainwright Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Maintains Target Price $38 - Moomoo
Pacira Q2 Earnings & Revenues Beat, 2026 Sales Outlook Cut - The Globe and Mail
Pacira BioSciences, Inc. Stock 12‑Month Price Target Raised to $30, Implies 9% Upside - TradingView
PCRX Maintained by Needham -- Price Target Raised to $33.00 - GuruFocus
RBC Adjusts Price Target on Pacira Biosciences to $25 From $24, Maintains Sector Perform Rating - Moomoo
Pacira BioSciences (NASDAQ:PCRX) Price Target Raised to $33.00 - MarketBeat
Pacira BioSciences, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Pacira BioSciences Inc (PCRX) (Q2 2026) Earnings Call Highlights: Revenue Growth and Strategic Pivots - GuruFocus
Pacira BioSciences Inc (PCRX) (Q2 2026) Earnings Call Highlights: Revenue Growth and Strategic ... - Yahoo Finance
PCRX SWOT Analysis: Strong Financial Recovery and Growth Potential Revealed in 10-Q Filing - GuruFocus
Earnings call transcript: Pacira BioSciences posts solid Q2 2026 revenue beat - Investing.com
Pacira BioSciences Q2 Earnings Call Highlights - TradingView
Is Pacira BioSciences Inc (PCRX) Undervalued After Q2 Earnings B - GuruFocus
Pacira Biosciences Inc (PCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.12%
0.05%
자본화:
|
볼륨(24시간):